Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2004-2010

  Naughtin, M ^a   Dyason, J C ^b   Mardy, S ^a   Sorn, S ^c   Von Itzstein, M ^b   Buchy, P ^a  

^a INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^b GRIFFITH UNIVERSITY   (Australia)

^c Ministry of Agriculture   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; HEMAGGLUTININ; OSELTAMIVIR; SIALIDASE; VALINE; ZANAMIVIR;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CAMBODIAN H5N1 VIRUSES CLADE 1; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG SPECIFICITY; GENE AMPLIFICATION; GENE MUTATION; GENETIC DRIFT; HUMAN; INFLUENZA VIRUS A H5N1; NONHUMAN; NUCLEOTIDE SEQUENCE; POULTRY; PRIORITY JOURNAL; RECEPTOR BINDING; VIRUS ISOLATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; NEURAMINIDASE; OSELTAMIVIR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SWINE;

EID: 79955546685     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01773-10     Document Type: Article

References (53)

1. Abed, Y., M. Baz, and G. Boivin. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 11:971-976.
2. Amaro, R. E., X. Cheng, I. Ivanov, D. Xu, and J. A. McCammon. 2009. Characterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations. J. Am. Chem. Soc. 131:4702-4709.
3. Auewarakul, P., et al. 2007. An avian influenza H5N1 virus that binds to a human-type receptor. J. Virol. 81:9950-9955. (Pubitemid 350067698)
4. Ayora-Talavera, G., et al. 2009. Mutations in H5N1 influenza virus hemagglutinin that confer binding to human tracheal airway epithelium. PLoS One 4:e7836.
5. Boltz, D. A., et al. 2009. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J. Gen. Virol. 91:949-959.
6. Buchy, P., et al. 2009. Molecular epidemiology of clade 1 influenza A viruses (H5N1), Southern Indochina Peninsula, 2004-2007. Emerg. Infect. Dis. 15:1641-1644.
7. Buchy, P., et al. 2007. Influenza A/H5N1 virus infection in humans in Cambodia. J. Clin. Virol. 39:164-168.
8. Buxton, R. C., et al. 2000. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal. Biochem. 280:291-300.
9. Cavailler, P., et al. 2010. Seroprevalence of anti-H5 antibody in rural Cambodia, 2007. J. Clin. Virol. 48:123-126.
10. Chen, L. M., C. T. Davis, H. Zhou, N. J. Cox, and R. O. Donis. 2008. Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog. 4:e1000072.
11. Connor, R. J., Y. Kawaoka, R. G. Webster, and J. C. Paulson. 1994. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 205:17-23.
12. Couceiro, J. N., J. C. Paulson, and L. G. Baum. 1993. Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res. 29:155-165.
13. Gambaryan, A., et al. 2006. Evolution of the receptor binding phenotype of influenza A (H5) viruses. Virology 344:432-438. (Pubitemid 43049630)
14. Gubareva, L. V., L. Kaiser, M. N. Matrosovich, Y. Soo-Hoo, and F. G. Hayden. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183:523-531.
15. Gubareva, L. V., R. G. Webster, and F. G. Hayden. 2002. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 53:47-61.
16. Herlocher, M. L., et al. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54:99-111. (Pubitemid 34327688)
17. Hoffmann, E., G. Neumann, Y. Kawaoka, G. Hobom, and R. G. Webster. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97:6108-6113.
18. Hurt, A. C., J. K. Holien, and I. G. Barr. 2009. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53:4433-4440.
19. Hurt, A. C., J. K. Holien, M. Parker, A. Kelso, and I. G. Barr. 2009. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83:10366-10373.
20. Hurt, A. C., S. Lowther, D. Middleton, and I. G. Barr. 2010. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antiviral Res. 87:361-366.
21. Hurt, A. C., et al. 2007. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 73:228-231.
22. Ilyushina, N. A., et al. 2008. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 52:3889-3897.
23. Ilyushina, N. A., J. P. Seiler, J. E. Rehg, R. G. Webster, and E. A. Govorkova. 2010. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog. 6:e1000933.
24. Ito, T., et al. 1997. Receptor specificity of influenza A viruses correlates with the agglutination of erythrocytes from different animal species. Virology 227:493-499. (Pubitemid 27241043)
25. Jackson, D., W. Barclay, and T. Zurcher. 2005. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J. Antimicrob. Chemother. 55:162-169.
26. Lackenby, A., C. Thompson, and J. Democratis. 2008. The potential impact of neuraminidase inhibitor resistant influenza. Curr. Opin. Infect. Dis. 21:626-638.
27. Landon, M. R., et al. 2008. Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble. Chem. Biol. Drug Des. 71:106-116.
28. Lu, B., H. Zhou, D. Ye, G. Kemble, and H. Jin. 2005. Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. J. Virol. 79:6763-6771. (Pubitemid 40677308)
29. Matrosovich, M., T. Matrosovich, J. Carr, N. A. Roberts, and H. D. Klenk. 2003. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77:8418-8425.
30. McKimm-Breschkin, J. L., P. W. Selleck, T. B. Usman, and M. A. Johnson. 2007. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg. Infect. Dis. 13:1354-1357.
31. Meijer, A., et al. 2009. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15:552-560.
32. Nicholls, J. M., A. J. Bourne, H. Chen, Y. Guan, and J. S. Peiris. 2007. Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses. Respir. Res. 8:73.
33. Rameix-Welti, M. A., et al. 2006. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob. Agents Chemother. 50:3809-3815.
34. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
35. Richard, M., et al. 2008. Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors. J. Clin. Virol. 41:20-24.
36. Rogers, G. N., and J. C. Paulson. 1983. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology 127:361-373.
37. Russell, R. J., et al. 2006. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. 443:45-49.
38. Stevens, J., et al. 2008. Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J. Mol. Biol. 381:1382-1394.
39. Stoner, T. D., et al. 2010. Antiviral susceptibility of avian and swine influenza of the N1 neuraminidase subtype. J. Virol. 84:9800-9809.
40. Suwannakarn, K., et al. 2009. Molecular evolution of H5N1 in Thailand between 2004 and 2008. Infect. Genet. Evol. 9:896-902.
41. Thompson, C. I., W. S. Barclay, and M. C. Zambon. 2004. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. J. Antimicrob. Chemother. 53:759-765.
42. Tisdale, M. 2000. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10:45-55.
43. Uchida, Y., et al. 2008. Molecular epidemiological analysis of highly pathogenic avian influenza H5N1 subtype isolated from poultry and wild bird in Thailand. Virus Res. 138:70-80.
44. Vines, A., et al. 1998. The role of influenza A virus hemagglutinin residues 226 and 228 in receptor specificity and host range restriction. J. Virol. 72:7626-7631. (Pubitemid 28377900)
45. Wan, X.-F., et al. 2008. Evolution of highly pathogenic H5N1 avian influenza viruses in Vietnam between 2001 and 2007. PLoS One 3:e3462.
46. Webby, R. J., et al. 2004. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363:1099-1103. (Pubitemid 38452781)
47. Wetherall, N. T., et al. 2003. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41:742-750.
48. Woods, J. M., et al. 1993. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetyl- neuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37:1473-1479.
49. World Health Organization. 2010. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO, 18 October 2010. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/avian- influenza/country/cases-table-2010-10-18/en/index.html.
50. Yen, H.-L., et al. 2005. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49:4075-4084.
51. Yen, H. L., et al. 2006. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol. 80:8787-8795.
52. Yen, H. L., A. S. Monto, R. G. Webster, and E. A. Govorkova. 2005. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J. Infect. Dis. 192:665-672.
53. Zambon, M., and F. G. Hayden. 2001. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 49:147-156.